Teleflex Inc.

Overview Key strengths Key risks Good scale and product diversity across seven business lines. Competition with products from larger companies such as Becton Dickinson&Co., Medtronic PLC, Boston Scientific Corp., and others. Mid-single-digit revenue growth driven by a high-margin innovative product pipeline. Downward pressure on margins due to inflationary environment. Solid track record of acquisition integration. Higher reliance on mergers and acquisition (M&A) business development activity compared with similarly rated peers. We believe the company now has a significant portion of its revenue (about 25%) stemming from advanced fast-growing products (i.e. UroLift, MANTA, and hemostatic products). We forecast that Teleflex? UroLift System, a minimally invasive technology for treating benign prostatic hyperplasia symptoms, will continue its robust growth in the

...We expect Teleflex' innovative products (i.e. UroLift, MANTA, and hemostatic products) to drive above-average organic growth in the coming years. We believe the company now has a significant portion of its revenue (about 25%) stemming from advanced fast-growing products (i.e. UroLift, MANTA, and hemostatic products). We forecast that Teleflex' UroLift System, a minimally invasive technology for treating benign prostatic hyperplasia symptoms, will continue its robust growth in the coming years as the COVID-19 impact abates. We forecast that the company's core product portfolio will continue to benefit from steady mid-single-digit organic growth, generally in...

Full Report